CD Skripsi
Efek Inhibitor Proteasom Terhadap Kadar Kolesterol Total Pada Tikus Model Aterosklerosis
Hypercholesterolemia is an important factor in the formation of atherosclerosis. Previous research has shown that proteasome inhibitors can reduce the enzyme 3-hydroxy-3-methylglutaryl-coenzyme a synthase (HMG-CoA synthase) mRNA levels which plays a role in cholesterol synthesis. Objective of this study was to analyze the effect of proteasome inhibitor on total cholesterol levels of atherosclerosis model in the progression stage. Eighteen Wistar male rats (±8-12 weeks, 160-250 grams) divided into 3 groups: control group, atherosclerosis group and proteasome inhibitor-assigned atherosclerosis group. Proteasome inhibitor administered was bortezomib at a dose of 50 µg/kg/BW/day intraperitoneally on day 1 and 3. Atherosclerosis induced by giving high lipid feeds (2% cholesterol, 5% goat fat and 0,2% cholic acid) for 4 days and vitamin D3 (700.000 IU/kg) on the first day. After 4 days of treatment, the rats were terminated and serum total cholesterol levels were measured using the CHOD-PAP (Cholesterol Oxidase-Peroxidase Aminoantypirin) method. The result showed significant differences between atherosclerosis and control groups. But, there were no significant differences between atherosclerosis+bortezomib and atherosclerosis groups. This study concluded that the administration of 50 µg/kg bortezomib for four days in the rats model of atherosclerosis has no significant effect on total cholesterol level.
Keywords: Atherosclerosis, proteasome inhibitor, total cholesterol
Tidak tersedia versi lain